Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Oct 05, 2023

BUY
$57.89 - $64.73 $578 - $647
10 Added 0.28%
3,573 $207,000
Q2 2023

Jul 11, 2023

SELL
$63.71 - $70.74 $13,442 - $14,926
-211 Reduced 5.59%
3,563 $227,000
Q1 2023

Apr 20, 2023

BUY
$65.71 - $74.53 $657 - $745
10 Added 0.27%
3,774 $261,000
Q4 2022

Feb 14, 2023

SELL
$68.48 - $81.09 $22,529 - $26,678
-329 Reduced 8.04%
3,764 $270,000
Q3 2022

Nov 14, 2022

BUY
$0.13 - $76.84 $0 - $537
7 Added 0.17%
4,093 $291,000
Q2 2022

Aug 08, 2022

BUY
$72.62 - $79.98 $653 - $719
9 Added 0.22%
4,086 $315,000
Q1 2022

May 06, 2022

BUY
$61.48 - $73.72 $553 - $663
9 Added 0.22%
4,077 $298,000
Q4 2021

Feb 02, 2022

BUY
$53.63 - $62.52 $536 - $625
10 Added 0.25%
4,068 $254,000
Q3 2021

Nov 12, 2021

BUY
$59.17 - $69.31 $2,899 - $3,396
49 Added 1.22%
4,058 $240,000
Q2 2021

Aug 10, 2021

BUY
$61.91 - $67.42 $557 - $606
9 Added 0.22%
4,009 $268,000
Q1 2021

Apr 29, 2021

BUY
$59.34 - $66.74 $534 - $600
9 Added 0.23%
4,000 $253,000
Q4 2020

Feb 10, 2021

BUY
$57.74 - $65.43 $519 - $588
9 Added 0.23%
3,991 $248,000
Q3 2020

Nov 09, 2020

BUY
$57.43 - $63.64 $516 - $572
9 Added 0.23%
3,982 $240,000
Q2 2020

Aug 05, 2020

SELL
$54.82 - $64.09 $19,296 - $22,559
-352 Reduced 8.14%
3,973 $234,000
Q1 2020

May 11, 2020

BUY
$46.4 - $67.43 $92 - $134
2 Added 0.05%
4,325 $241,000
Q4 2019

Jan 28, 2020

BUY
$49.21 - $64.19 $11,121 - $14,506
226 Added 5.52%
4,323 $278,000
Q2 2019

Jul 17, 2019

SELL
$44.62 - $49.34 $17,848 - $19,736
-400 Reduced 8.89%
4,097 $186,000
Q1 2019

Apr 09, 2019

SELL
$45.12 - $53.8 $90,240 - $107,600
-2,000 Reduced 30.78%
4,497 $215,000
Q1 2018

May 23, 2018

BUY
$59.92 - $68.98 $389,300 - $448,163
6,497 New
6,497 $412,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $124B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Quad Cities Investment Group, LLC Portfolio

Follow Quad Cities Investment Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quad Cities Investment Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quad Cities Investment Group, LLC with notifications on news.